Identity
- Security key
- 18104
- Ticker
- LNAI
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2014-11-18
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- LNAI
Detail
Enriched 2026-08-14 20:47
- Market cap
- $10,654,641.5
- Shares outstanding (class)
- 4,533,890
- Shares outstanding (weighted)
- 4,533,890
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 29
- Location
- SUITE 906 LOS ANGELES, CA
- Homepage
- https://www.renovarogroup.com
- Description
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.